See the DrugPatentWatch profile for lurbinectedin

Based on the information provided, I was unable to find specific data on how lurbinectedin exposure affects fetal development. However, I can provide some context around lurbinectedin and general information about fetal development risks associated with anti-cancer drugs.

Lurbinectedin is an anti-cancer drug being developed by PharmaMar. It is a selective inhibitor of oncogenic transcription. Although there is no specific information on lurbinectedin's effects on fetal development, it is generally known that many anti-cancer drugs can pose risks to the fetus during pregnancy [1].

Anti-cancer drugs can have various effects on fetal development, including increased risk of miscarriage, birth defects, and developmental issues [2]. These risks can depend on factors such as the specific drug, the stage of pregnancy, and the dosage. It is important for healthcare providers to carefully consider these risks when prescribing medications to pregnant individuals or those of childbearing age.

In summary, while there is no specific information on how lurbinectedin exposure affects fetal development, it is generally known that many anti-cancer drugs can pose risks to the fetus during pregnancy. Pregnant individuals or those of childbearing age should consult their healthcare providers before starting any new medications.

Sources:
[1] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/bulk-downloads/
[2] National Cancer Institute. (2015, May 11). Cancer Treatment and Pregnancy. Retrieved from https://www.cancer.gov/about-cancer/treatment/types/pregnancy/patient/cancer-treatment-and-pregnancy-pdq